Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Osimertinib Plus Capivasertib in EGFRm Advanced Non-small Cell Lung Cancer (NSCLC) Participants With PIK3CA/AKT1/PTEN Alterations Who Had Progressed on First-line Osimertinib Monotherapy or Plus Chemotherapy: a First-in-human, Phase Ib/Ⅱa Study (PRECISION)

NCT07486648 is registered in ClinicalTrials.gov with Shanxi Province Cancer Hospital as lead sponsor.

NCT NCT07486648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07486648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Osimertinib Plus Capivasertib in EGFRm Advanced Non-small Cell Lung Cancer (NSCLC) Participants With PIK3CA/AKT1/PTEN Alterations Who Had Progressed on First-line Osimertinib Monotherapy or Plus Chemotherapy: a First-in-human, Phase Ib/Ⅱa Study (PRECISION)
Lead sponsor
Shanxi Province Cancer Hospital
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
May 15, 2026
Completion date
December 31, 2028
Enrollment
53 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non-small-cell lung cancer, lung cancer (non-small cell), lung cancer (nsclc)